Month: March 2025

Breast cancer remains one of the most prevalent malignancies among women worldwide, and its hormone receptor-positive, HER2-negative (HR+/HER2−) subtype accounts for nearly 70% of all cases. In recent years, the combination of CDK4/6 inhibitors (CDK4/6i) with endocrine therapy (ET) has become the gold standard for first-line treatment in metastatic settings. However, once progression occurs on CDK4/6i-based regimens, the optimal path forward is less clearly defined, presenting a persistent challenge in clinical decision-making.

Hormone receptor-positive (HR⁺) breast cancer accounts for approximately 70% of all breast cancer cases, representing a large population in need of effective treatment strategies. In recent years, first-line treatment with…

As breast cancer continues to rank as the most frequently diagnosed cancer among women worldwide, hormone receptor-positive, HER2-negative (HR+/HER2⁻) disease remains its most common subtype. In recent years, combining CDK4/6…

Breast cancer remains the leading malignancy threatening women’s health worldwide. Among its subtypes, hormone receptor-positive/HER2-negative (HR+/HER2−) breast cancer is the most common and typically has a better prognosis, having now entered the era of chronic disease management. In the context of long-term, whole-course management—often spanning over a decade—the concept of “patient-centered care” has become central to clinical practice. Reducing the frequency of medication through long-acting therapies can significantly improve the patient experience, enhance quality of life, and boost adherence.

Breast cancer is the most common malignancy among women worldwide, with the HR+/HER2- subtype being one of the most prevalent forms. With the rapid advancement of medical technology and the continuous emergence of new therapies, patient survival has significantly improved, bringing hope to many. Recently, the novel oral HDAC inhibitor entinostat received official approval from China’s National Medical Products Administration (NMPA) for use in combination with an aromatase inhibitor (AI) to treat patients with HR+/HER2- locally advanced or metastatic breast cancer who have relapsed or progressed following endocrine therapy. On July 25, the first prescriptions were issued in Guangdong, Guangxi, Beijing, and other provinces in China, marking a major milestone. This significant breakthrough offers a new treatment option for patients with HR+/HER2- advanced breast cancer and is expected to reshape the current therapeutic landscape.

On March 13, 2025, the "2025 St. Gallen Breast Cancer Conference (SGBCC) Best Poster Awards" were grandly announced. A total of 482 posters were accepted for this year's SGBCC

PARP inhibitors (PARPi) have ushered in a new era of precision treatment for prostate cancer. Multiple studies have confirmed that patients with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair deficiency mutations (HRRm) can benefit from this therapeutic approach. At the recently held 2025 European Association of Urology(EAU25) conference , a single-arm Phase II PROact study conducted by Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School，Nanjing University, was reported. The study demonstrated promising preliminary efficacy and safety of the combination of olaparib, abiraterone, and prednisone in the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). UroStream was honored to invite Prof. Junlong Zhuang from Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School,Nanjing University, and Prof. Samson Chan from Department of Surgery, Tuen Mun Hospital, HONG KONG, to engage in a dialogue and share the latest advancements and clinical experiences in precision therapy for prostate cancer.

The 19th St. Gallen  Breast Cancer Conference (SGBCC) took place in Vienna, Austria, from March 12 to 15, 2025. As one of the most prestigious biennial academic events in breast cancer research, SGBCC gathers leading global experts to discuss evolving treatment strategies for early breast cancer, voting on recommendations that shape clinical practice. Notably, this year’s SGBCC will feature a China-focused session, marking a significant milestone. Additionally, Prof. Benlong Yang from Fudan University Shanghai Cancer Center has been named SGBCC’s “Youth Education Ambassador” and “Social Media Ambassador.” This marks the first time a Chinese expert has been awarded such distinctions at SGBCC.

The highly anticipated 19th St. Gallen Breast Cancer Conference (SGBCC) is taking place from March 12 to 15, 2025, in Vienna, Austria. This year, the conference features a special “Voice…